DISTRIBUTION. (i) If syndicated, names and addresses of Managers and underwriting commitments: Not Applicable Not Applicable.
DISTRIBUTION. (i) Method of distribution: Non-syndicated - Dealer(s): Société Générale Tour Société Générale 17 Cours Valmy
DISTRIBUTION. (i) Method of distribution: Non-syndicated - Dealer(s): Société Générale Bank&Trust 00, xxxxxx Xxxxx Xxxxxx 2420 Luxembourg Luxembourg
DISTRIBUTION. (i) Method of distribution: Non-syndicated - Dealer(s): Société Générale
DISTRIBUTION. (i) Method of distribution: Non-syndicated - Dealer(s):
DISTRIBUTION. Not Applicable Not Applicable Not Applicable Yes. Note that the designation "yes" simply means that the Notes are intended upon issue to be deposited with one of the ICSDs as common safekeeper, and registered in the name of a nominee of one of the ICSDs acting as common safekeeper, that is, held under the New Safekeeping Structure, and does not necessarily mean that the Notes will be recognized as eligible collateral for Eurosystem monetary policy and intra day credit operations by the Eurosystem either upon issue or at any or all times during their life. Such recognition will depend upon the ECB being satisfied that Eurosystem eligibility criteria have been met
DISTRIBUTION. (i) Name(s) and address(es), to the extent known to the Issuer, of the Managers / Distributors in the various countries where the offer takes place: See paragraph 107 of Part A.
DISTRIBUTION. Société Générale Tour Société Générale 17, Cours Valmy 92987 Paris La Défense Cedex
DISTRIBUTION. Cabozantinib is highly protein bound in vitro in human plasma (≥ 99.7%). Based on the population- pharmacokinetic (PK) model, the volume of distribution (Vz) is approximately 212 L (SE: ± 2.7%). Protein binding was not altered in subjects with mild or moderately impaired renal or hepatic function (1).
DISTRIBUTION. After a single, deep subcutaneous administration, the mean absolute bioavailability of lanreotide in healthy subjects was 73.4, 69.0, and 78.4% for the 60 mg, 90 mg, and 120 mg doses, respectively. Mean Cmax values ranged from 4.3 to 8.4 ng/mL during the first day. Single-dose linearity was demonstrated with respect to AUC and Cmax, and showed high inter-subject variability. Lanreotide autogel (depot formulation) showed sustained release of lanreotide with a half-life of 23 to 30 days. Mean serum concentrations were > 1 ng/mL throughout 28 days at 90 mg and 120 mg and > 0.9 ng/mL at 60 mg. In patients with GEP-NETs treated with Lanreotide 120 mg every 4 weeks, steady state concentrations were reached after 4 to 5 injections and the mean trough serum lanreotide concentrations at steady state ranged from 5.3 to 8.6 ng/mL. Information from human studies regarding distribution of lanreotide is not available (8).